1. Research progress in the treatment of interstitial lung disease related to polymyositis/dermatomyositis
- Author
-
ZHENG Xiaofeng and XU Ling
- Subjects
polymyositis ,dermatomyositis ,interstitial lung disease ,medication ,Medicine - Abstract
Polymyositis/dermatomyositis (PM/DM) is a heterogeneous autoimmune disease characterized by inflammatory cell infiltration in skeletal muscles with unknown etiology. The incidence of interstitial lung disease (ILD) in PM/DM is higher. ILD is the most important factor affecting its prognosis. Existing evidence suggests that there is significant heterogeneity in PM/DM-related ILD, which requires individualized treatment based on the onset form, progression rate, lesion involvement range, laboratory examination, presence of adverse prognostic factors, and response to treatment of ILD. This article summarizes the research progress in the treatment of PM/DM-related ILD in recent years, including the selection of traditional therapeutic drugs, timing of medication, and new drugs attempted in this field in clinical practice (such as biological agents and Janus kinase inhibitors), intravenous immunoglobulin, anti-fibrotic drugs, and potentially effective non-drug treatment methods, aiming at providing reference for clinical doctors to formulate PM/DM-ILD treatment plans and improve patient prognosis.
- Published
- 2024
- Full Text
- View/download PDF